文献速递眼底病与葡萄膜炎

CLS-TA治疗非感染性葡萄膜炎性黄斑水肿的扩展研究

Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA).
PubMed 文献 · Br J Ophthalmol · 2021-03-12

MAGNOLIA扩展研究评估了脉络膜上腔注射曲安奈德(CLS-TA)治疗非感染性葡萄膜炎继发黄斑水肿的长期疗效与安全性,48周内CLS-TA组需要挽救治疗的中位时间显著长于对照组,约50%患者末次给药后9个月内无需额外治疗。

要点

  • CLS-TA组48周内需要挽救治疗的中位时间为257天,对照组为55.5天。
  • 28例CLS-TA治疗患者中14例(50%)在第二次治疗后约9个月内无需挽救治疗。
  • 无需挽救治疗者第48周平均视力增益12.1个字母,黄斑中心亚区厚度平均降低174.5微米。

核心结论

  • 约50%的患者在末次CLS-TA给药后长达9个月内无需额外治疗。

研究设计与样本

  • MAGNOLIA为PEACHTREE三期随机试验的扩展研究,53例符合条件的患者中33例入组(28例CLS-TA,5例对照)。

主要发现

  • 48周内CLS-TA组需要挽救治疗的中位时间为257天,假对照组为55.5天。
  • 参与MAGNOLIA的28例CLS-TA患者中14例(50%)在第二次治疗后约9个月内无需挽救治疗。
  • 无需挽救治疗的CLS-TA患者第48周平均视力增益12.1个字母,黄斑中心亚区厚度平均降低174.5微米。

临床怎么用

  • CLS-TA脉络膜上腔注射可延长非感染性葡萄膜炎继发黄斑水肿患者的挽救治疗间隔。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the extended efficacy and safety of suprachoroidal triamcinolone acetonide injectable suspension (CLS-TA) among patients with macular oedema (ME) secondary to non-infectious uveitis (NIU). METHODS: Patients with uveitic ME were treated with suprachoroidal CLS-TA at baseline and week 12 of the Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial (PEACHTREE) study. Time to rescue was evaluated over 24 additional weeks for MAGNOLIA. Safety data, visual acuity and retinal central subfield thickness (CST) reduction were also evaluated. Of the 53 eligible patients (46 CLS-TA and 7 control), 33 patients were enrolled (28 CLS-TA and 5 control). RESULTS: Over the entire 48-week period for PEACHTREE and MAGNOLIA, the median time to rescue therapy was 257 days versus 55.5 days for the CLS-TA and sham-control arms, respectively. Of 28 CLS-TA treated patients who participated in MAGNOLIA, 14 (50%) did not require rescue therapy through approximately 9 months after the second treatment. Among CLS-TA patients not requiring rescue, there was a mean gain of 12.1 letters and mean CST reduction of 174.5 µm at week 48. No serious adverse events related to study treatment were observed. CONCLUSION: Approximately 50% of patients did not require additional treatment for up to 9 months following the last CLS-TA administration.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Khurana RN, Merrill P, Yeh S, et al. Extension study of the safety and efficacy of CLS-TA for treatment of macular oedema associated with non-infectious uveitis (MAGNOLIA). Br J Ophthalmol. 2021. PMID: 33712478. doi:10.1136/bjophthalmol-2020-317560

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。